The next big thing people should pay attention to is that in the next year, there are going to be readouts from three other medicines that lower amyloid plaques: gantenerumab, donanemab, and lecanemab. And those first results will come out in the fall and going into next year. And those are going to be really informative about if we’re able to move forward with these new disease modifying treatments...
The next big thing people should pay attention to is that in the next year, there are going to be readouts from three other medicines that lower amyloid plaques: gantenerumab, donanemab, and lecanemab. And those first results will come out in the fall and going into next year. And those are going to be really informative about if we’re able to move forward with these new disease modifying treatments. The update is that one is under review at the FDA, lecanemab for accelerated approval, and that submission has already taken place. And the FDA has to announce their decision by January so that will be coming. And then both gantenerumab and lecanemab have announced that their trials will be ending, and they’ll be reporting results in October and November. So that’ll be really important. And then there’ll be other results coming out as well, soon after that from other trials. So it’s going to be a busy time in terms of clinical trial results for Alzheimer’s.
